Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study.
Naomi AlpertJoseph L RappBridget MarcellinoWil Lieberman-CribbinRaja FloresEmanuela TaioliPublished in: JNCI cancer spectrum (2020)
COVID-19 patients with cancer may have a higher risk for adverse outcomes. Although there was no statistically significant difference in mortality, COVID-19 patients with cancer have statistically significantly higher risk of thromboembolism and sepsis. Further research is warranted into the potential effects of cancer treatments on inflammatory and immune responses to COVID-19 and on the efficacy of anticoagulant therapy in these patients.
Keyphrases
- coronavirus disease
- sars cov
- papillary thyroid
- immune response
- end stage renal disease
- squamous cell
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- acute kidney injury
- atrial fibrillation
- intensive care unit
- venous thromboembolism
- oxidative stress
- lymph node metastasis
- squamous cell carcinoma
- respiratory syndrome coronavirus
- stem cells
- dendritic cells
- risk assessment
- patient reported outcomes
- risk factors
- young adults
- human health
- mesenchymal stem cells